Introduction {#Sec1}
============

Approximately 2--3 % of the US population suffers from neuropathic pain \[[@CR1]\]. A common cause of neuropathic pain is post-herpetic neuralgia (PHN), a complication of herpes zoster. PHN may persist for weeks, or years, after the initial shingles rash has healed \[[@CR2]\]. Although studies have demonstrated that the overall incidence of PHN following acute zoster is approximately 20 %, the incidences of PHN for individuals over the age of 50 and 75 years are as high as 40 and 75 %, respectively \[[@CR3]--[@CR6]\]. Because of the acute pain associated with PHN, quality of life is often negatively affected. In addition, PHN may interfere with daily activities, and may lead to insomnia, fatigue, depression and anxiety \[[@CR7]\].

Antiepileptic medications and tricyclic antidepressants have been the mainstay of pharmacological treatment of neuropathic pain. Gabapentin and pregabalin are the only US Food and Drug Administration (FDA)-approved antiepileptics indicated for the treatment of neuropathic pain. Gabapentin and pregabalin are oral agents that bind to the α2δ subunit of calcium channels in neurons and are believed to regulate neurotransmitter levels \[[@CR8]\]. In two large multicentre studies, patients with PHN treated with gabapentin experienced significant reductions in pain compared with patients receiving placebo \[[@CR9], [@CR10]\]. Patients on gabapentin also showed significantly less sleep interference and improvements in mood \[[@CR11], [@CR12]\]. Pregabalin has been shown to be effective and tolerable in patients treated for neuropathic pain associated with PHN \[[@CR13]\]. The beneficial effect of tricyclic antidepressants (e.g., amitriptyline, nortriptyline) in PHN treatment has also been demonstrated in several clinical trials \[[@CR14]--[@CR17]\].

This study used a large administrative claims database from a national US health plan to examine dosing patterns, therapy outcomes, and healthcare utilization and costs among patients with PHN treated with gabapentin and pregabalin. Because both gabapentin and pregabalin must be titrated to an effective dosage and continued for an adequate duration to alleviate the pain associated with PHN, we were interested to determine how many patients with PHN receive effective dosages of these therapies and how long they continue them in real-world practice. Furthermore, we examined which additional therapies were added to gabapentin or pregabalin or to what other therapies patients switched. Opioid analgesics, which are not first-line therapies for PHN, are also efficacious \[[@CR18]--[@CR20]\], but second-line use of them is controversial because of their risk for potential abuse, concerns regarding their long-term safety, and side effects such as constipation, nausea and drowsiness. Finally, we examined the costs for patients with PHN initiating treatment with gabapentin or pregabalin.

Methods {#Sec2}
=======

Study Design and Data Source {#Sec3}
----------------------------

This was a retrospective claims database study using medical and pharmacy claims data and enrollment information from a proprietary claims database affiliated with OptumInsight. Individuals covered by this health plan, 26.9 million adults during the study period, were geographically diverse, with greatest representation in the South and Midwest US census regions. All study data were accessed using techniques compliant with the Health Insurance Portability and Accountability Act of 1996, and no identifiable protected health information was extracted for this study \[[@CR21]\]. As such, this study was exempt from Institutional Review Board approval.

Patient Identification {#Sec4}
----------------------

The study population was commercially insured and Medicare Advantage health plan members with PHN initiating treatment with gabapentin or pregabalin. Patients had one or more pharmacy claim for either drug during the identification period of January 2006 to February 2009; the date of the first observed pharmacy claim was defined as the *index date* and the medication was defined as the *index therapy*. Patients were continuously enrolled in the health plans, with medical and pharmacy benefits, for at least 6 months before the index date (*pre-index period*) and 12 months after the index date (*post-index period*; included the index date). They had more than one medical claim with a primary International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis for PHN (053.1×) from the start of the pre-index period through 2 days after index date, and no claims for the index therapy during the pre-index period \[[@CR22]\]. The entire period of observation was 1 July 2005 through 27 February 2010; each patient was observed for 18 months.

Study Measures {#Sec5}
--------------

### Demographic and Clinical Characteristics {#Sec6}

Age, sex and US census region of health plan enrollment were obtained from enrollment data. A Charlson co-morbidity index score was calculated from ICD-9-CM diagnosis codes on medical claims in the pre-index period \[[@CR23], [@CR24]\]. Pharmacy claims were examined to identify pre-index use of non-index medications that could be prescribed for pain (see Appendix 1, Online Resource).

### Dosing Patterns {#Sec7}

Index therapy dosing patterns were measured during the post-index period. All dosing variables were based on calculations of mean daily dosage. Mean daily dosage for each index therapy fill was computed as: \[(drug strength × quantity dispensed)/days supply\]. Mean daily dosage for each day a patient possessed the index therapy was recorded; if a patient possessed the index therapy from more than one prescription fill on any given day, we assumed that gabapentin or pregabalin were being titrated and, consequently, the mean daily dosage values associated with each fill were summed for that day.

"Mean dosage while in possession," was computed as: \[∑(each day's mean daily dosage value)/number of days possessed\]; days when patients did not possess index therapies (i.e., mean daily dosage = 0) were excluded. "Mean daily dosage excluding gaps of ≥30 days" was calculated using the equation above but excluding days when patients did not possess their index therapies if those days represented a minimum 30-day gap in therapy. Mean maximum dosage was the highest mean daily dosage value observed for at least 14 consecutive days; mean maximum dosage was not computed for patients with fewer than 14 consecutive days of the same dosage. Time to mean maximum dosage was the number of days from the index date to the first day of the mean maximum dosage. Dose reduction occurred when mean daily dosage dropped from the mean maximum dosage by ≥300 mg for gabapentin and by ≥150 mg for pregabalin \[[@CR25], [@CR26]\].

Patients who received minimally effective dosages of index therapies were identified. A minimally effective dosage was defined as an individual fill of the index therapy with a mean daily dosage of the labeled minimally effective dosage for PHN (≥1,800 mg for gabapentin and ≥150 mg for pregabalin) \[[@CR25], [@CR26]\]. For pregabalin, an alternative minimally effective dosage threshold of ≥300 mg/day was also examined; this dosage has similar efficacy to the effective dosage of gabapentin \[[@CR25], [@CR26]\]. Patients who did not have one or more index therapy pharmacy claim with a minimally effective dosage of either therapy were considered to have attained sub-therapeutic dosages.

### Therapy Outcomes {#Sec8}

Discontinuation, persistence, switch from index therapy and addition of pain medications (other than pregabalin and gabapentin) to the index therapy were measured during the post-index period. Discontinuation of index therapy was defined as a gap in therapy of at least 30 days. The discontinuation date was defined by the "run-out date" (i.e., fill date + days supply) of the last index therapy fill prior to the first observed gap. Discontinuation could occur between two consecutive therapy fills or between the last observed index therapy fill and the end of the post-index period. Persistence was the number of days from the index date to the discontinuation date. Index therapy switch was defined as at least one pharmacy claim for a non-index neuropathic pain medication (Appendix 1, Online Resource) and no subsequent index therapy fills. The class of medication to which the patients switched was identified. Neuropathic pain medication additions were defined as at least one claim for a condition-specific non-index therapy after the index date (not including the index therapy), prior to discontinuation of the index therapy, and no fills of the added therapy during pre-index period (Appendix 1, Online Resource).

### Cost and Utilization Outcomes {#Sec9}

All-cause healthcare resource utilization and costs were measured in the pre- and post-index periods. Inpatient stays, emergency room (ER) visits, outpatient facility visits, and physician office visits were counted per PHN patient per month. Costs per PHN patient per month were the sum of health plan and patient-paid amounts and were adjusted to 2009 US dollars using the Consumer Price Index \[[@CR27]\]. Cost measures included inpatient costs, ER visit costs, outpatient facility visit costs, physician office visit costs, other services costs, total medical costs, outpatient pharmacy costs, and total healthcare (medical + pharmacy) costs.

Analysis {#Sec10}
--------

Variables were analysed descriptively. Results were stratified by index therapy cohort and, within cohort, by patients who received minimally effective and sub-therapeutic index therapy dosages. *T* tests were used to identify significant differences between the means of continuous variables; chi-squared statistics were used for binary variables.

Results {#Sec11}
=======

Dosing Patterns and Therapy Outcomes {#Sec12}
------------------------------------

A total of 1,645 patients (939 patients receiving gabapentin and 706 receiving pregabalin) met the study inclusion criteria (Fig. [1](#Fig1){ref-type="fig"}). Pre-index demographic and clinical characteristics are shown in Table [1](#Tab1){ref-type="table"}. Detailed dosing patterns and therapy outcomes by index therapy cohort are shown in Table [2](#Tab2){ref-type="table"}. The mean daily dosage excluding any gaps of 30 days was 826 mg for gabapentin and 187 mg for pregabalin. On average, it took patients 30.2 days to reach the mean maximum dosage of gabapentin (969.5 mg) and 30.3 days to reach the mean maximum dosage of pregabalin (221.8 mg). Patients receiving gabapentin or pregabalin remained on the therapy for an average of 72.9 and 79.5 days, respectively (*p* = 0.160). Patients treated with gabapentin (10 %) were more likely to have their dosages reduced than were patients receiving pregabalin (4 %, *p* \< 0.001).Fig. 1Sample selection and attritionTable 1Demographic and clinical characteristics by index therapy cohort^a^CharacteristicGabapentin (*n* = 939)Pregabalin (*n* = 706)*P* value^b^Age, years (mean ± SD)^c^63.82 ± 15.0161.99 ± 14.610.014Age, years 18--44105 (11.18)83 (11.76)NS 45--64380 (40.47)334 (47.31)0.006 ≥65454 (48.35)289 (40.93)0.003Sex Male368 (39.19)299 (42.35)NS Female571 (60.81)407 (57.65)NSInsurance type Commercial693 (73.80)583 (82.58)\<0.001 Medicare advantage246 (26.20)123 (17.42)\<0.001Region Northeast88 (9.37)57 (8.07)NS Midwest338 (36.00)182 (25.78)\<0.001 South370 (39.40)369 (52.27)\<0.001 West143 (15.23)98 (13.88)NSQuan-Charlson co-morbidity score (mean ± SD)^c^1.05 ± 1.580.90 ± 1.360.040Quan-Charlson co-morbidity score 0495 (52.72)383 (54.25)NS 1204 (21.73)165 (23.37)NS 2111 (11.82)83 (11.76)NS 354 (5.75)40 (5.67)NS 435 (3.73)17 (2.41)NS ≥540 (4.26)18 (2.55)NSPre-index opioid use646 (68.80)504 (71.39)NS*NS* not significant^a^Values are n (%) except where otherwise stated^b^All 2-way continuous comparisons between gabapentin and pregabalin index therapy cohorts were performed using *t* tests; comparisons of binary variables between cohorts were evaluated with chi-squared statistics^c^Continuous variableTable 2Dosing patterns and therapy outcomes by index therapy cohortVariableGabapentin (*n* = 939)^a^Pregabalin (*n* = 706)^a^*P* value^b^Daily dose excluding any gaps of 30 days, mg (mean ± SD)826.26 ± 559.27187.08 ± 102.88--Daily dose while in possession, mg (mean ± SD)^c^875.12 ± 602.41199.51 ± 109.68--Time to maximum dose days (mean ± SD)^d^30.24 ± 70.70^e^30.26 ± 70.63^f^--Maximum dose, mg (mean ± SD)^d^969.52 ± 737.66^e^221.83 ± 146.55^f^--Time on index therapy, days (mean ± SD)^g^72.87 ± 93.5279.51 ± 96.53NSNumber of fills for index therapy (mean ± SD)^h^3.08 ± 3.183.30 ± 3.37NSReduction in dose of index therapy during post-index period \[n (%)\]^d^87 (9.93)^e^29 (4.39)^f^\<0.001Gap in therapy \[n (%)\]877 (93.40)661 (93.63)NSSwitch from index therapy \[n (%)\]544 (57.93)394 (55.81)NSAdded to index therapy \[n (%)\]348 (37.06)218 (30.88)0.009*NS* not significant; -- signifies statistical analyses not performed^a^Number of patients used for statistical calculation except where otherwise stated^b^*T* tests were used to identify significant differences between the means of continuous variables; chi-squared statistics were used for binary variables^c^Dose while in possession was the daily dose only on those days that the patient had the index drug (e.g. excluded all gap days, included gaps fewer than 30 days)^d^For patients with ≥14 days on one maximum dose^e^876 patients^f^661 patients^g^Number of days prior to evidence of gap or switch from index medication^h^Throughout the entire follow-up period

The mean daily dosages for the first fills of gabapentin or pregabalin were 760 mg and 175 mg, respectively (Appendix 2, Online Resource). Only slightly more than half of all patients had more than one fill of their index therapies (Fig. [2](#Fig2){ref-type="fig"}). Patients treated with gabapentin appeared to experience upward dosage titration through the first five fills of therapy, whereas patients treated with pregabalin appeared to be titrated upward for the first six to seven fills of therapy based on the mean dosage. Over half of patients switched from their index therapies during the post-index period (Fig. [3](#Fig3){ref-type="fig"}; Table [2](#Tab2){ref-type="table"}). Of those who switched, approximately one-third switched to opioids (gabapentin, 35 %; pregabalin, 31 %; *p* = 0.258; Fig. [4](#Fig4){ref-type="fig"}a). Additionally, 37 % of patients in the gabapentin cohort and 31 % of patients in the pregabalin cohort added medication to their index therapies (Table [2](#Tab2){ref-type="table"}); opioids were added by 57 % of patients taking gabapentin and 58 % of patients taking pregabalin (Fig. [4](#Fig4){ref-type="fig"}b).Fig. 2Number of index therapy fillsFig. 3Patients who added to or switched from index therapyFig. 4Classes of medications **a** to which patients switched or **b** that were added to index therapy. *TCA* tricyclic antidepressants

Dosing Patterns and Therapy Outcomes of Patients Receiving Minimally Effective and Sub-therapeutic Dosages of Therapy {#Sec13}
---------------------------------------------------------------------------------------------------------------------

Only 134 (14 %) patients taking gabapentin received at least one fill of the minimally effective dosage (≥1,800 mg/day) and the mean time to reach this dosage was about 10 weeks (Table [3](#Tab3){ref-type="table"}). In contrast, 611 (87 %) of patients taking pregabalin received at least one fill of the minimally effective dosage of ≥150 mg/day and 194 (27 %) had at least one fill at ≥300 mg/day. The mean times to reach daily dosages of ≥150 mg or ≥300 mg of pregabalin were about 5 weeks and 9.2 weeks, respectively. Patients receiving sub-therapeutic dosages of gabapentin or pregabalin were more likely than those who had received a minimally effective dosage to be switched to antidepressants (data not shown; 0.2 % minimally effective, 3 % sub-therapeutic; *p* = 0.004) or opioids (data not shown; 27 % minimally effective, 38 % sub-therapeutic; *p* \< 0.001).Table 3Dosing patterns and therapy outcomes in patients receiving minimally effective doses of index therapy^a,\ b^VariableGabapentin ≥1800 mg/day (*n* = 134)^c^Pregabalin ≥150 mg/day (*n* = 611)^c^Pregabalin ≥300 mg/day (*n* = 194)^c^Daily dose excluding any gaps of 30 days (mg)1710.87 ± 836.42203.15 ± 101.16310.66 ± 116.15Daily dose while in possession (mg)^d^1892.38 ± 851.85217.06 ± 107.41335.43 ± 118.52Time to maximum dose (days)^e^68.94 ± 89.26^f^33.18 ± 73.01^g^64.54 ± 95.26^h^Maximum dose (mg)^e^2224.24 ± 1,007.34^f^242.68 ± 146.90^g^396.85 ± 168.19^h^Reduction in dose of index therapy during post-index period \[n (%)\]^e^35 (27.78)^f^29 (5.08)^g^27 (14.59)^ha^Minimally effective doses were defined as ≥1800 mg/day of gabapentin and ≥150 mg/day of pregabalin. Sub-therapeutic doses were defined as less than the minimally effective daily dose^b^Values are mean ± SD except where otherwise stated^c^Number of patients used for statistical calculation except where otherwise stated^d^Dose while in possession was the daily dose only on those days that the patient had the index drug (e.g. excluded all gap days, included gaps fewer than 30 days)^e^For patients with ≥14 days on one maximum dose^f^126 patients^g^571 patient^h^185 patients

Patients treated with sub-therapeutic dosages of gabapentin (94 %) were more likely to have gaps in therapy than were those receiving minimally effective dosages (87 %, *p* = 0.002; Table [4](#Tab4){ref-type="table"}). The mean total days on index therapy and mean total number of fills for index therapy were significantly higher for patients treated with minimally effective dosages of gabapentin compared to those treated with sub-therapeutic dosages (all *p* \< 0.001). The mean total days on index therapy (*p* = 0.001) and mean total number of fills for index therapy (*p* \< 0.001) were also significantly higher for patients treated with minimally effective dosages of pregabalin (≥150 mg/day) compared with those treated with lower dosages.Table 4Dosing patterns and therapy outcomes in patients receiving minimally effective or sub-therapeutic doses of index therapy^a^VariableGabapentinPregabalinMinimally effective (*n* = 134)Sub-therapeutic (*n* = 805)*P* value^b^Minimally effective (*n* = 611)Sub-therapeutic (*n* = 95)*P* value^b^Gap in therapy \[n (%)\]117 (87.31)760 (94.41)0.002568 (92.96)93 (97.89)NSSwitch from index therapy \[n (%)\]68 (50.75)476 (59.13)NS341 (55.81)53 (55.79)NSTime on index therapy, days (mean ± SD)^c^119.89 ± 109.2165.04 ± 88.32\<0.00183.06 ± 99.9556.71 ± 66.740.001Number or fills for index therapy (mean ± SD)^d^5.15 ± 3.442.74 ± 3.00\<0.0013.47 ± 3.472.24 ± 2.47\<0.001*NS* not significant^a^Minimally effective doses were defined as ≥1800 mg/day of gabapentin and ≥150 mg/day of pregabalin. Sub-therapeutic doses were defined as less than the minimally effective daily dose^b^Sub-therapeutic versus minimally effective dose within index therapy cohorts. All 2-way continuous comparisons between gabapentin and pregabalin index therapy cohorts were performed using *t* tests; comparisons of binary variables were evaluated with chi-squared statistics^c^Number of days prior to evidence of gap or switch from index medication^d^Throughout the entire follow-up period

Healthcare Resource Use and Cost {#Sec14}
--------------------------------

There were no differences in healthcare utilization between patients who were going to receive gabapentin or pregabalin in the pre-index period with the exception of the mean count of all-cause inpatient admissions, which were higher in patients receiving gabapentin compared with patients receiving pregabalin (*p* = 0.012; Table [5](#Tab5){ref-type="table"}). In the post-index period, patients receiving gabapentin had significantly higher mean all-cause monthly office visit counts than did patients receiving pregabalin (*p* = 0.033). The gabapentin cohort had higher mean office visit costs per month compared with the pregabalin cohort in the post-index period (*p* = 0.048). However, patients receiving pregabalin had significantly higher mean all-cause pharmacy costs than did patients receiving gabapentin (*p* *\<* 0.001). The mean all-cause total healthcare costs per month were US \$1,136 and US \$1,007 in the pre-index period for the gabapentin and pregabalin cohorts, respectively (*p* = 0.244) and US \$1,749 and US \$1,570 in the post-index period for the gabapentin and pregabalin cohorts, respectively (*p* = 0.512, Table [5](#Tab5){ref-type="table"}).Table 5Pre- and post-index healthcare utilization and costs per patient per month by index therapy^a^VariablePre-indexPost-indexGabapentin (*n* = 939)Pregabalin (*n* = 706)*P* value^b^Gabapentin (*n* = 939)Pregabalin (*n* = 706)*P* value^b^All-cause healthcare utilization Office visits1.38 ± 1.351.44 ± 1.24NS2.61 ± 3.292.30 ± 2.640.033 Outpatient visits0.50 ± 0.750.48 ± 0.72NS0.82 ± 3.110.64 ± 2.74NS Inpatient admissions0.04 ± 0.090.03 ± 0.070.0120.04 ± 0.230.04 ± 0.41NS Emergency room visits0.11 ± 0.260.11 ± 0.28NS0.24 ± 1.110.15 ± 0.82NSAll-cause total healthcare cost (US\$)^c^1136 ± 25981007 ± 1879NS1749 ± 61171570 ± 4935NSAll-cause pharmacy cost (US\$)^c^247 ± 418251 ± 345NS423 ± 755585 ± 727\<0.001All-cause medical cost (US\$)^c^889 ± 2501756 ± 1814NS1326 ± 5831985 ± 4753NS Inpatient stay337 ± 1377277 ± 1441NS390 ± 3136315 ± 4101NS Emergency room29 ± 9127 ± 82NS61 ± 35035 ± 280NS Outpatient visit266 ± 1376226 ± 566NS454 ± 4457327 ± 1952NS Office visit220 ± 745193 ± 412NS336 ± 1065258 ± 4970.048 Other medical37 ± 13734 ± 116NS86 ± 70450 ± 199NS*NS* not significant^a^Values are mean ± SD^b^Gabapentin versus pregabalin index therapy cohorts. All 2-way continuous comparisons between gabapentin and pregabalin index therapy cohorts were performed using *t* tests^c^All values are expressed in 2009 US dollars \[[@CR27]\]

Discussion {#Sec15}
==========

This retrospective administrative claims data-based study was undertaken to better understand the dosing patterns, therapy outcomes, and healthcare utilization and costs for patients with PHN who initiated treatment with gabapentin or pregabalin.

Prior studies have indicated that gabapentin can be initiated at 900 mg/day for treatment of neuropathic pain, and that additional titration to 1,800 mg/day is often necessary for full efficacy \[[@CR28], [@CR29]\]. However, dosages of up to 3,600 mg/day may be required in some patients \[[@CR28], [@CR29]\]. The recommended duration for gabapentin titration for PHN is 3--8 weeks \[[@CR30]\]. Our study found that the mean daily dosage and average maximum dosage for patients receiving gabapentin were 826 and 969 mg, respectively, which both were lower than the labeled dosage of 1,800 mg. Only 14 % of the patients receiving gabapentin were titrated to the minimally effective dosage of 1,800 mg or higher; the average maximum dosage for them was 2,224 mg and it took approximately 10 weeks to reach this level. Patients who received the minimally effective dosage of gabapentin remained on therapy for an average of 17 weeks.

The recommended dosage of pregabalin for PHN is 150--300 mg daily \[[@CR30], [@CR31]\]. If pain relief is inadequate following 2--4 weeks of pregabalin at 300 mg/day, the dosage may be increased to 600 mg daily \[[@CR13]\]. In our study, the mean daily dosage for patients taking pregabalin was 187 mg, the mean maximum dosage was 222 mg, and it took 30 days on average to reach the maximal level. Approximately 87 % of patients achieved dosages of pregabalin ≥150 mg/day, but only 27 % of patients received dosages of pregabalin ≥300 mg/day. The mean maximum dosage of patients receiving 150 mg/day was 243 mg and the average time to reach this maximum dosage was 33 days. Patients who received the minimally effective dosage of pregabalin (≥150 mg/day) remained on therapy for an average of 12 weeks.

Our data illustrate that many patients with PHN do not achieve the minimally effective dosage of gabapentin (1,800 mg/day) or pregabalin at dosage levels (≥300 mg/day) with similar efficacy to the minimally effective dosage of gabapentin. This may have been due to several patient factors including co-morbidities, polypharmacy or issues with tolerability that would make it clinically unfeasible for a patient to reach a minimally effective dosage. Additionally, providers' clinical judgements about patients' analgesic responses at less than the labeled dosing levels, or without titration, may also be a factor when prescribing these therapies. Adverse events may be a contributing factor to why patients may not have achieved the minimally effective dosage following treatment initiation. Prior studies have shown that adverse events are a principal reason why people stop taking gabapentin or pregabalin \[[@CR32]\]. However, some patients may have discontinued their medication rather than escalating to minimally effective dosage levels because they were not achieving sufficient pain management.

Half of the patients who took gabapentin or pregabalin in our study did not fill more than one prescription, and over half of the patients switched therapies. Of the patients who switched, one-third switched to opioids. A study by Gore et al. \[[@CR33]\] focused specifically on the dosages prescribed in clinical practice and changes in the use of other neuropathic pain-related medications after the initiation of gabapentin or pregabalin and found similar results. In this study, patients with PHN increased opioid use after the initiation of gabapentin and decreased opioid use after the initiation of pregabalin. As in our study, more patients received a minimally effective dosage of pregabalin (69 %, ≥150 mg/day) than they did gabapentin (14 %, ≥1,800 mg/day); however, our study found that a higher proportion of pregabalin patients added an opioid after treatment initiation than did those receiving gabapentin. Gore et al. \[[@CR33]\] study also found that patients treated with pregabalin were more likely to attain therapeutic dosage levels earlier than were those patients who were prescribed gabapentin.

Our study was subject to certain limitations. The data used for this study come from a managed-care population and therefore the results may not be applicable to patients who are uninsured or underinsured. In addition, there are inherent limitations with the use of administrative claims data. First, some clinical and disease-specific parameters that might affect choice of treatment and study outcomes (e.g., adverse events, pain severity) are not available in claims data. Second, the presence of a diagnosis code on a medical claim is not a positive identification of a disease, as the diagnosis code may be incorrectly coded or codes may not precisely capture the diagnosis of interest or extent of disease. However, our analysis required a primary diagnosis that may have mitigated the likelihood of misclassification. Third, it is not possible to determine whether patients use medications as prescribed. Also, estimates of healthcare utilization and costs provided are all-cause, not PHN-specific. Lastly, in this study, opioids may have been used for other pain-related co-morbidities and it is possible that some patients did not reach optimal dosages because of side effects due to polypharmacy; these were not examined.

Current guidelines for pharmacological treatment of neuropathic pain are based on the results of randomized clinical trials and may not reflect "real-world" patterns of use in usual-care settings. Our results indicate that gabapentin and pregabalin are not being used effectively for the treatment of PHN. Sub-optimal dosing may lead to inadequate treatment response, which can in turn lead to early discontinuation of therapy, to switching to second-line therapies for PHN, or to addition of other analgesics. Taken together, these factors could possibly lead to unnecessarily high use of opioids which are currently "at the center of a major public health crisis of addiction, misuse, abuse, overdose and death" \[[@CR34]--[@CR36]\].

Conclusion {#Sec16}
==========

These findings show that many patients with PHN do not achieve the minimally effective dosages of gabapentin or pregabalin. The study also highlights possible issues with titration, the attainment of optimal dosages, and the tolerability of therapy in clinical practice. Further tolerability studies are warranted in studies of the pharmacological treatment of PHN.
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